Oculis Holding AG (FRA:CR5) Current Accrued Expense : €8.56 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Current Accrued Expense?

Oculis Holding AG's Current Accrued Expense for the quarter that ended in Mar. 2024 was €8.56 Mil.

Oculis Holding AG's quarterly Current Accrued Expense declined from Sep. 2023 (€8.89 Mil) to Dec. 2023 (€6.22 Mil) but then increased from Dec. 2023 (€6.22 Mil) to Mar. 2024 (€8.56 Mil).

Oculis Holding AG's annual Current Accrued Expense increased from Dec. 2021 (€2.93 Mil) to Dec. 2022 (€8.12 Mil) but then declined from Dec. 2022 (€8.12 Mil) to Dec. 2023 (€6.22 Mil).

Oculis Holding AG Current Accrued Expense Historical Data

The historical data trend for Oculis Holding AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Current Accrued Expense Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

3.11

2.93

8.12

6.22

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial							-	8.47	8.89	6.22	8.56

Oculis Holding AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Oculis Holding AG Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (FRA:CR5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

OCS:USA OCS:Iceland

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines